Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 915810-67-2
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the clinical use of caplacizumab during breastfeeding. Because caplacizumab is a large protein molecule with a molecular weight of about 28,000 Da, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. Use of the drug after 2 weeks postpartum may minimize transfer to the infant.[1] Until more data become available, caplacizumab should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant. Some opinion recommends that patients with acquired thrombotic thrombocytopenic purpura not breastfeed because anti-platelet sIgA might be present in milk and may adversely affect the infant.[2]
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
References
- 1.
- Krysko KM, Dobson R, Alroughani R, et al. Family planning considerations in people with multiple sclerosis. Lancet Neurol. 2023;22:350–66. [PubMed: 36931808]
- 2.
- Alijotas-Reig J. Acquired thrombotic thrombocytopenic purpura and pregnancy: More light than shade but controversies remain. Thromb Res. 2017;156:195–7. [PubMed: 28697902]
Substance Identification
Substance Name
Caplacizumab
CAS Registry Number
915810-67-2
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubMedLinks to PubMed
- Review Tremelimumab.[Drugs and Lactation Database (...]Review Tremelimumab.. Drugs and Lactation Database (LactMed®). 2006
- Review Blinatumomab.[Drugs and Lactation Database (...]Review Blinatumomab.. Drugs and Lactation Database (LactMed®). 2006
- Review Vedolizumab.[Drugs and Lactation Database (...]Review Vedolizumab.. Drugs and Lactation Database (LactMed®). 2006
- Review Ansuvimab.[Drugs and Lactation Database (...]Review Ansuvimab.. Drugs and Lactation Database (LactMed®). 2006
- Review Atezolizumab.[Drugs and Lactation Database (...]Review Atezolizumab.. Drugs and Lactation Database (LactMed®). 2006
- Caplacizumab - Drugs and Lactation Database (LactMed®)Caplacizumab - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...